Allergy And Infectious Diseases Research federal funding in FY2024

Allergy And Infectious Diseases Research dollars inside FY2024

85.8% locates FY2024 inside Allergy And Infectious Diseases Research's $36,365,364,946.68 extract when the packet nests the FY cell. A thick research file: thousands of FY rows, still not a count of unique investigators. Parent without the year: /programs/93.855/ (CFDA 93.855). Parent without the CFDA: /fiscal-years/2024/ (FY2024 federal spending). Outlays are not this field.

FY2024 holds most of the published 93.855 book. That share is a rollup fact, not a ranking of labs. Do not invent labs, trials, or investigators. aging research (93.866), cardiovascular research (93.837), and biomedical training (93.859) sit on other keys. Campaign-finance filings do not fund these USAspending obligations. Correlation with outbreak headlines is not causation.

Allergy And Infectious Diseases Research as a catalog title beside FY2024

The official title is ALLERGY AND INFECTIOUS DISEASES RESEARCH. SpendingVault does not grade study designs or institute priorities. $31,188,305,841.33 is a FY2024 obligation sum, not a performance score. Mixing aging research (93.866), cardiovascular research (93.837), and biomedical training (93.859) into $31,188,305,841.33 would invent a combined total the packet never computed. Program-wide obligations are $36,365,364,946.68 on 13,068 awards.

The FY cell is 85.8% of the program-wide $36,365,364,946.68 book in this extract. Later bulk files can move both the dollars and the 9,328-award count. The All programs index still lists other catalog lines. The FY2024 federal spending hub still lists other FY2024 programs. Neither parent equals this cell.

9,328 FY2024 awards are not a census of labs, trials, or investigators

9,328 is the FY2024 award-record count on CFDA 93.855, not 13,068 program-wide rows treated as labs, trials, or investigators. Continuations and modifications add lines. This page does not publish a typical payment from $31,188,305,841.33 and 9,328. Unique recipients remain unpublished.

What the Allergy And Infectious Diseases Research FY2024 table omits

No outlays, no named campuses, no trial enrollments, no pathogen split. Quote Allergy And Infectious Diseases Research and FY2024 with $31,188,305,841.33. Keep CFDA 93.855 in the citation. FEC donation tables are a different dataset and do not fund this cell.

Citing Allergy And Infectious Diseases Research in FY2024

Open /programs/93.855/ for CFDA 93.855, /fiscal-years/2024/ for FY2024 federal spending, /programs/ for All programs, and /ties/ for All spending ties. Those parents are larger than this cell. Keep both join sides on the same line as $31,188,305,841.33. USAspending.gov remains the source.

A ties page exists because two tables meet. One table is CFDA 93.855. The other is fiscal year 2024. $31,188,305,841.33 is the obligation sum on that intersection, not a forecast and not a claim that Allergy And Infectious Diseases Research caused infection rates to fall. Step off this pair through the internal links. Keep Allergy And Infectious Diseases Research and FY2024 together when citing $31,188,305,841.33. CFDA 93.855's program-wide award-record count is 13,068, not a FY2024-only census of labs, trials, or investigators. Obligations of $31,188,305,841.33 are not outlays. Original filings remain on USAspending.gov for this 93.855 × FY2024 pair. Do not add parent hubs into this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. The 85.8% share is $31,188,305,841.33 divided by the program-wide $36,365,364,946.68, not a budget score. Unique recipients remain unpublished on this Allergy And Infectious Diseases Research FY2024 join. Agency and place-of-performance splits are omitted from this packet. Quote CFDA 93.855, fiscal year 2024, and $31,188,305,841.33 in one sentence. The All programs index and All spending ties index are larger than this cell. A later USAspending ingest can restate $31,188,305,841.33 without changing the join keys. This page is not a lab, trial, or investigator census. 9,328 FY2024 award records are not 13,068 program-wide rows.

Questions

How much allergy and infectious-disease research was obligated in FY2024?

USAspending.gov records $31,188,305,841.33 in CFDA 93.855 obligations tagged to fiscal year 2024 across 9,328 awards. That cell is 85.8% of the program-wide $36,365,364,946.68 book, not an outlay.

Do 9,328 awards mean 9,328 laboratories?

No. 9,328 is an FY2024 award-record count on a thick research file, including continuations. The program-wide extract lists 13,068 awards. Recipients are unpublished. USAspending.gov remains the source for this pair. USAspending.gov remains the source for this pair.

Does this include aging or heart-disease research?

No. Those listings use other 93-series keys. Mixing them into $31,188,305,841.33 would invent a combined NIH research total the packet never computed. USAspending.gov remains the source for this pair. USAspending.gov remains the source for this pair.

Does $31,188,305,841.33 equal research cash already spent?

No. $31,188,305,841.33 is an obligation aggregate. Outlays are unpublished. FEC donations do not fund this USAspending cell. USAspending.gov remains the source for this pair. USAspending.gov remains the source for this pair. USAspending.gov remains the source for this pair.